Ketoconazole as second-line treatment for Cushing’s disease after transsphenoidal surgery: systematic review and meta-analysis
暂无分享,去创建一个
[1] T. C. Rodrigues,et al. Evaluation of ketoconazole as a treatment for Cushing’s disease in a retrospective cohort , 2022, Frontiers in Endocrinology.
[2] P. Chanson,et al. Consensus on diagnosis and management of Cushing's disease: a guideline update. , 2021, The lancet. Diabetes & endocrinology.
[3] C. Boguszewski,et al. Effectiveness of Medical Treatment of Cushing’s Disease: A Systematic Review and Meta-Analysis , 2021, Frontiers in Endocrinology.
[4] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.
[5] L. Nieman,et al. Approach to the Patient Treated with Steroidogenesis Inhibitors. , 2021, The Journal of clinical endocrinology and metabolism.
[6] R. Ferrigno,et al. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials , 2020, Frontiers in Endocrinology.
[7] M. Fleseriu,et al. Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery , 2020, Expert review of endocrinology & metabolism.
[8] M. Fleseriu,et al. Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. , 2019, The lancet. Diabetes & endocrinology.
[9] F. Beuschlein,et al. Therapeutic options after surgical failure in Cushing's disease: A critical review. , 2019, Best practice & research. Clinical endocrinology & metabolism.
[10] D. Greenblatt,et al. Ketoconazole and Liver Injury: A Five‐Year Update , 2019, Clinical pharmacology in drug development.
[11] O. Dekkers,et al. Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis , 2018, Pituitary.
[12] Jacques Young,et al. Hepatic safety of ketoconazole in Cushing's syndrome: results of a Compassionate Use Programme in France. , 2018, European journal of endocrinology.
[13] V. Mendoza,et al. LONG-TERM OUTCOME OF THE DIFFERENT TREATMENT ALTERNATIVES FOR RECURRENT AND PERSISTENT CUSHING DISEASE. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[14] M. Fleseriu,et al. Updates on the role of adrenal steroidogenesis inhibitors in Cushing’s syndrome: a focus on novel therapies , 2016, Pituitary.
[15] A. Tabarin,et al. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. , 2015, The Journal of clinical endocrinology and metabolism.
[16] A. Colao,et al. The Treatment of Cushing's Disease. , 2015, Endocrine reviews.
[17] A. Vicente,et al. Análisis de los resultados del tratamiento de la enfermedad de Cushing en los hospitales de Castilla-La Mancha , 2015 .
[18] C. Lamas,et al. Assessment of the outcomes of the treatment of Cushing's disease in the hospitals of Castilla-La Mancha. , 2015, Endocrinologia y Nutricion.
[19] S. Khare,et al. Clinical, biochemical and imaging characteristics of Cushing's macroadenomas and their long‐term treatment outcome , 2014, Clinical endocrinology.
[20] P. Chanson,et al. Ketoconazole in Cushing's disease: is it worth a try? , 2014, The Journal of clinical endocrinology and metabolism.
[21] M. Gadelha,et al. Efficacy of medical treatment in Cushing's disease: a systematic review , 2014, Clinical endocrinology.
[22] Qing-mei Tao,et al. Ketoconazole associated hepatotoxicity: a systematic review and meta- analysis. , 2013, Biomedical and environmental sciences : BES.
[23] M. Fleseriu,et al. New avenues in the medical treatment of Cushing’s disease: corticotroph tumor targeted therapy , 2013, Journal of Neuro-Oncology.
[24] M. Fleseriu,et al. Medical management of Cushing’s disease: what is the future? , 2012, Pituitary.
[25] P. Jones,et al. Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature. , 2011, The Journal of clinical endocrinology and metabolism.
[26] G. Arnaldi,et al. Approach to the patient with possible Cushing's syndrome. , 2009, The Journal of clinical endocrinology and metabolism.
[27] V. Montori,et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.
[28] E. Laws,et al. Late recurrences of Cushing's disease after initial successful transsphenoidal surgery. , 2008, The Journal of clinical endocrinology and metabolism.
[29] M. Fleseriu,et al. Second-line treatment for Cushing's disease when initial pituitary surgery is unsuccessful , 2007, Current opinion in endocrinology, diabetes, and obesity.
[30] M. Salvatore,et al. Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease , 1998, Clinical endocrinology.
[31] M. Boscaro,et al. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients , 1991, Clinical endocrinology.
[32] P. Tugwell,et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .
[33] I. Morange,et al. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease. , 2008, European journal of endocrinology.
[34] R. Fahlbusch,et al. Long-term results after microsurgery for Cushing disease: experience with 426 primary operations over 35 years. , 2008, Journal of neurosurgery.
[35] M. Boscaro,et al. Recovery of Bone Mineral Density after Surgical Cure, but not by Ketoconazole Treatment, in Cushing’s Syndrome , 2001, Osteoporosis International.